Adalimumab in the therapy of uveitis in childhood

British Journal of Ophthalmology

Volumn 91, Issue 3, 2007, Pages 274-276

  Mansour, Ahmad M ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLAXIS; APLASTIC ANEMIA; CHILDHOOD; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; INJECTION SITE REACTION; OPTIC NEURITIS; PANCYTOPENIA; POLYARTHRITIS; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; UVEITIS; VASCULITIS; CHILD; DRUG ANTAGONISM; NOTE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 33947582285     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.108050     Document Type: Editorial

References (20)

1. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
2. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12.
3. Mushtaq B, Saeed T, Situnayake RO, et al. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye. Published Online First: 7 April 2006. doi: 10.1038/sj.eye.6702352.
4. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113(12):2317-23.
5. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5.
6. Kump LI, Cervantes Castaneda RA, Androud SN, et al. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006;113:1874-7.
7. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
8. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24.
9. Kotaniemi K, Savolainen A, Karma A, et al. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol 2003;48:489-502.
10. Gale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006;33:231-7.
11. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in spondylarthropathy patients: a retrospective study. Ann Rheum Dis 2006;65:1631-4.
12. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003;25:1700-21.
13. Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J Rheumatol Suppl 2005;74:3-7.
14. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicily profiles. Semin Arthritis Rheum 2005;34(5 Suppl 1):19-22.
15. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005;34(5 Suppl 1):12-18.
16. Kamal KM, Madhavan SS, Hornsby JAA, et al. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 2006;73(6):718-24.
17. Tauber T, Turetz J, Barash J, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 2006;10:26-9.
18. Chung JH, Van Stavern GP, Frohman LP, et al. Adalimumab-associated optic neuritis. J Neurol Sci 2006;244:133-6.
19. Woolley JM. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53.
20. Mansour AM. Infliximab treatment of posterior uveitis. Ophthalmology 2004;111:197-8.